Summary
Normal marrow cell kinetics were studied by flow cytometry with computer analysis in 11 children with malignancies who received high-dose MTX followed by CF rescue. Nine children with hematological tumors in remission each received an infusion of MTX over 24 h, followed by delayed CF rescue. In 8 of the 9, an accumulation of cells in early to mid-S phase and a decrease of cells in G2/M phase were observed at 24–48 h after the beginning of the MTX infusion. At 144 h after MTX infusion this kinetic perturbation disappeared and the DNA histogram returned to the same state as before therapy. Two children who had malignant bone tumors without marrow infiltration each received an infusion of MTX over 6 h with early CF rescue following an initial IV injection of vincristine. They did not have any prominent perturbation of marrow cell kinetics after MTX exposure, except for a transient increase of cells in G2/M phase.
These results confirm that with the high-dose MTX therapy described above for hematological malignancies the impairment of marrow cell kinetics was much more severe and was soon followed by complete recovery, whereas with the therapy for solid tumors the impairment was much slighter.
Similar content being viewed by others
Abbreviations
- MTX:
-
methotrexate
- CF:
-
citrovorum factor
- FCM:
-
flow cytometry
References
Bleyer WA (1978) The clinical pharmacology of methotrexate: New application of an old drug. Cancer 41: 36
Chen TS, Wenczak BA, Huang KC (1983) Transport of methotrexate in cortical slices of monkey kidney: effect of organic anions and vincristine. J Pharmacol Exp Ther 226: 645
Fried J, Mandel M (1979) Multi-user system for analysis of data from flow cytometry. Comput Prog Biomed 10: 218
Fyfe MJ, Goldman ID (1973) Characteristics of the vincristime-induced augmentation of methotrexate uptake in Ehrlrich ascites tumor cells. J Biol Chem 248: 5067
Howell SB, Krishan A, Frei E III (1979) Cytokinetic comparison of thymidine and leucovorin rescue of marrow in humans after exposure to high-dose methotrexate. Cancer Res 39: 1315
Howell SK, Wang YM, Hosoya R, Sutow WW (1980) Plasma methotrexate as determined by liquid chromatography, enzyme inhibition assay, and radioimmunoassay after high-dose infusion. Clin Chem 26: 734
Krishan A (1975) Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66: 188
Laerum OD, Frasund T (1981) Clinical application of flow cytometry: a review. Cytometry 2: 1
Sasaki K, Tanaka J, Fujimoto T (1984) Theoretically required urinary flow during high-dose methotrexate infusion. Cancer Chemother Pharmacol 13: 9
Sasaki K, Tanaka J, Murakami T, Matsuoka H, Fujimoto T, Taguchi H (1985) Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. Cancer Drug Delivery 2: 77
Vogler WR, Israili ZH, Soliman AGM, Moffitt S, Barlogie B (1981) Marrow cell kinetics in patients treated with methotrexate and citrovorum factor. Cancer 47: 215
Wang YM (1978) Observations on the clinical pharmacology of high-dose methotrexate in children. Cancer Bull 30: 181
Wang YM, Fujimoto T (1984) Clinical pharmacokinetics of methotrexate in children. Clin Pharmacokinet 9: 335
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tsurusawa, M., Sasaki, K., Matsuoka, H. et al. Flow cytometric analysis of marrow cell kinetics in children treated with high-dose MTX and CF rescue. Cancer Chemother. Pharmacol. 16, 277–281 (1986). https://doi.org/10.1007/BF00293992
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00293992